Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1454846-35-5
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of lorlatinib during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during lorlatinib therapy and for 7 days after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Lorlatinib
CAS Registry Number
1454846-35-5
Drug Class
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Signal Transduction Inhibitors
- Tyrosine Kinase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.[J Med Chem. 2014]Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, Cui JJ, Deal JG, Deng YL, Dinh D, et al. J Med Chem. 2014 Jun 12; 57(11):4720-44. Epub 2014 Jun 3.
- Review Trametinib.[Drugs and Lactation Database (...]Review Trametinib.. Drugs and Lactation Database (LactMed®). 2006
- Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.[Drug Metab Dispos. 2015]Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.Yamazaki S, Lam JL, Zou HY, Wang H, Smeal T, Vicini P. Drug Metab Dispos. 2015 Jan; 43(1):54-62. Epub 2014 Oct 27.
- Review Rucaparib.[Drugs and Lactation Database (...]Review Rucaparib.. Drugs and Lactation Database (LactMed®). 2006
- Review Gilteritinib.[Drugs and Lactation Database (...]Review Gilteritinib.. Drugs and Lactation Database (LactMed®). 2006
- Lorlatinib - Drugs and Lactation Database (LactMed®)Lorlatinib - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...